The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.
Males and females 30 to 70 years of age
The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)
High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L
The presence of severe rosacea as noted by the investigator global assessment.
Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.
Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment
Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.
Single group
Skin Barrier Oral Supplement
Dietary supplementSupplment powder
Transepidermal water loss (TEWL)
Change in the facial transepidermal water loss (TEWL) using the Vapometer.
Blood hs-CRP level
Change in blood hs-CRP level through blood spot testing
Intestinal permeability
Change in intestinal permeability through a urine based test by Genova Diagnostics
Intestinal permeability
Change in intestinal permeability through a urine based test by Genova Diagnostics
Fecal levels of calprotectin
Change in fecal levels of calprotectin through a stool sample
Fecal levels of calprotectin
Change in fecal levels of calprotectin through a stool sample
Inflammatory lesions on the face
Change in number of inflammatory lesions on the face
Inflammatory lesions on the face
Change in number of inflammatory lesions on the face
Facial erythema
Change in appearance of facial erythema measured by photographic analysis (BTBP 3D Camera System)
Facial erythema
Change in appearance of facial erythema measured by photographic analysis (BTBP 3D Camera System)
Click on the lead sponsor to view all of their trials.
